About
Psilera develops therapies aimed at neurological and psychiatric disorders by leveraging neuroplastogens, compounds that promote brain plasticity without hallucinogenic effects. The company builds a proprietary library of serotonergic compounds and applies computational tools to design molecules for conditions such as alcohol use disorder and frontotemporal dementia. Its research pipeline emphasizes non-hallucinogenic derivatives of psychedelic compounds to provide safe and scalable treatment options. Psilera integrates medicinal chemistry, neuroscience, and pharmacology to create small-molecule drugs that address unmet medical needs. Through this approach, the company seeks to expand treatment possibilities for patients facing hard-to-treat neurological conditions.
Team & affiliation
Founders: [object Object], [object Object].
Region context
Psilera is one of 6 Biotechnology companies we track in Tampa Bay, based in Tampa — about 5% of the region's 129 startups.
Tampa Bay — cybersecurity, fintech, and a growing health-tech cluster.
See the full Tampa Bay ecosystem →